Abstract: PD23-11
Sources of Funding: Procept Biorobotics

Introduction

Early data concerning Aquablation (water jet-based prostate ablation) for lower urinary tract symptoms due to benign prostatic hyperplasia has suggest efficacy similar to that of Transurethral Resection of the Prostate (TURP) in the short term. This study sought to examine the medium-term results with this technique.

Methods

A prospective single-arm multicenter trial was conducted at 3 centers in Australia and New Zealand with 2-year follow-up. Participants were men aged 50-80 years with moderate-to-severe lower urinary tract symptoms, prostates <80g and obstruction as determined by pressure-flow urodynamic studies. All patients underwent Aquablation with image guidance. Follow-up was performed at 1 and 2 years.

Results

Twenty-one men underwent Aquablation with a mean age of 69.7 (range 62-78) years and prostate volume of 57.2 (30-102) mL. Two-year follow-up was available in 16 subjects. Mean IPSS score improved from 22.8 at baseline to 6.8 at 12 months and 6.7 at 24 months. Qmax improved from 8.6 cc/sec at baseline to 14.8 sec at 24 months. PVR decreased from 116 cc at baseline to 38 cc at follow-up. There were no adverse events (> Clavien 3) between year 1 and year 2.

Conclusions

This phase II study provides evidence to support the medium-term safety and effectiveness of Aquablation for symptomatic BPH.

Funding

Procept Biorobotics